Alkem Laboratories

阿尔克姆实验室

on Saturday said it has launched

周六表示已推出

semaglutide

司美格鲁肽

injection in India, entering the fast-growing market for diabetes and

印度的注射剂市场，进入快速增长的糖尿病和

weight loss drug

减肥药

with a product priced at a starting weekly cost of Rs 450.

每周起始费用为 450 卢比的产品。

The drug, marketed under the brand names “Semasize”, “Obesema” and “Hepaglide”, is administered as a once-weekly subcutaneous injection. The company has introduced a pre-filled disposable injection pen priced at Rs 1,800 for a month’s dosage, translating into Rs 450 per week.

这种药物以“Semasize”、“Obesema”和“Hepaglide”品牌销售，每周一次皮下注射。该公司推出了一款预填充的一次性注射笔，一个月的剂量售价为1800卢比，相当于每周450卢比。

Alkem said it is also offering a reusable injection pen for higher maintenance doses, allowing patients to replace only the medication cartridge instead of buying a new device each time, a move aimed at reducing long-term treatment costs and improving adherence.

阿尔克姆表示，公司还提供了一种可重复使用的注射笔，用于较高的维持剂量，患者只需更换药物盒，而无需每次购买新设备。此举旨在降低长期治疗成本并提高患者的依从性。

The country’s most definitive MSME stage returns on March 24 in New Delhi. Register now for the ET MSME Awards 2025

该国最权威的中小微企业盛会将于3月24日在新德里回归。立即注册参加2025年《经济时报》中小微企业奖。

Add

添加

as a Reliable and Trusted News Source

作为一个可靠和值得信赖的新闻来源

Add Now!

立即添加！

(You can now subscribe to our

（你现在可以订阅我们的

Economic Times WhatsApp channel

经济时报WhatsApp频道

)

)

(You can now subscribe to our

（你现在可以订阅我们的

Economic Times WhatsApp channel

经济时报WhatsApp频道

)

)